MiMedx To Present At The Stem Cell Meeting On The Mesa
MARIETTA, Ga., Sept. 30, 2014 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spinal, Sports Medicine, Ophthalmic and Dental sectors of healthcare, announced today that Dr. Tom Koob, Ph.D., Chief Scientific Officer, will present at the Stem Cell Meeting on the Mesa. Dr. Koob will present on Tuesday, October 7, 2014, at 5:00PM Pacific Daylight Time.
The Stem Cell Meeting on the Mesa is a three-day conference bringing together key opinion leaders, senior executives and top decision-makers in the regenerative medicine and advanced therapies industry with the scientific community to advance cutting-edge research into cures. The meeting features a nationally recognized Scientific Symposium, attended by leading researchers and clinical experts from around the globe, in conjunction with the industry's premier annual Partnering Forum, the first and only event of its kind dedicated to facilitating connections in this sector. The three-day meeting held in La Jolla, California, begins on Tuesday, October 7, 2014 and concludes on Thursday, October 9, 2014.
Dr. Koob has published over 125 biomedical and biological articles and 12 book chapters, and he is listed as an inventor on over 40 issued and pending patents. MiMedx is actively involved in state-of-the-art scientific research directed towards a complete understanding of the mechanisms of action underlying the clinical effectiveness of the Company's dehydrated human amnion chorion membrane ("dHACM") allografts. Six scientific studies have been conducted on the effects of dHACM on human cells involved in wound healing and tissue regeneration. In all six of the studies completed to date, peer-reviewed articles have been published in the scientific literature. Dr. Koob has been instrumental in all of these studies and publications.
About MiMedx
MiMedx® is an integrated developer, processor and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include AmnioFix® and EpiFix®, our tissue technologies processed from human amniotic membrane that is derived from donated placentas. Through our donor program, mothers delivering full-term Caesarean section births can elect in advance of delivery to donate the placenta in lieu of having it discarded as medical waste. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx® is the leading supplier of amniotic tissue, having supplied over 275,000 allografts to date for application in the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental sectors of healthcare.
SOURCE MiMedx Group, Inc.